ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Valeant Trumps Endo In Fight For Salix

by Michael McCoy
March 23, 2015 | APPEARED IN VOLUME 93, ISSUE 12

Valeant Pharmaceuticals has raised its offer for the gastrointestinal drug firm Salix Pharmaceuticals with a new bid of $173.00 per share in cash, or about $15.8 billion. Valeant and Salix had signed a takeover deal in February that valued Salix at $158.00 per share. But earlier this month another drugmaker, Endo International, entered the fray with a $175.00 cash-and-stock bid. Valeant says its all-cash deal, although for less, brings more certainty. Salix apparently agrees and has accepted. Endo has withdrawn its offer.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment